ALDEYRA THERAPEUTICS INC (ALDX) Stock News
NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD
ALDX Latest News, Press Relases and Analysis
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
ALDX stock results show that Aldeyra Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission.
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics to Host Investor Roundtable Q&A
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Aldeyra stock jumps 8% on dermatitis drug updates (NASDAQ:ALDX)
Aldeyra Therapeutics (ALDX) shares jumped 8% on updates for two of its drug candidates for atopic dermatitis. Read more here.
3 Stocks at the Forefront of Personalized Medicine Trend
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly
FDA says more data needed to approve Aldeyra dry eye drug (NASDAQ:ALDX)
The FDA has declined to approve Aldeyra's (ALDX) drug reproxalap for dry eye disease, stating the company needs to run at least one additional study to show its effectiveness.
FDA says more studies needed to approve Aldeyra dry eye drug (NASDAQ:ALDX)
The FDA has declined to approve Aldeyra's (ALDX) drug reproxalap for dry eye disease, stating the company needs to run at least one additional study to show its effectiveness.